LinkedIn image ad examples

𝗜𝗻𝘃𝗲𝘀𝘁𝗲𝗲𝗿 𝗶𝗻 𝗵𝗲𝘁 𝗿𝗲𝗱𝗱𝗲𝗻 𝘃𝗮𝗻 𝗹𝗲𝘃𝗲𝗻𝘀 𝗺𝗲𝘁 𝗣𝘂𝗹𝘀𝗲𝟰𝗮𝗹𝗹.📈 Met een jaarlijkse rente van 8% en een looptijd van 4 jaar, biedt deze investering een uitstekende kans om uw kapitaal te laten groeien terwijl u bijdraagt aan een nobel doel. U investeert in levensreddende apparaten en helpt bij het plaatsen van meer AED's. Wilt u meer informatie ontvangen? Vraag vrijblijvend de brochure aan! Beleggen brengt risico's met zich mee. U kunt uw inleg verliezen. Lees het Basisprospectus op https://lnkd.in/eR5HJdqY voordat u een beleggingsbeslissing neemt.

𝗪𝗮𝗮𝗿 𝗶𝗻𝘃𝗲𝘀𝘁𝗲𝗲𝗿𝘁 𝘂 𝗲𝗶𝗴𝗲𝗻𝗹𝗶𝗷𝗸 𝗶𝗻 𝗺𝗲𝘁 𝗲𝗲𝗻 𝗼𝗯𝗹𝗶𝗴𝗮𝘁𝗶𝗲 𝘃𝗮𝗻 𝗣𝘂𝗹𝘀𝗲𝟰𝗮𝗹𝗹? Niet in één product, maar in een groeiend netwerk van AED’s in Europa. In veiligheid en toegankelijke zorg. En natuurlijk in een vaste rente van 8% per jaar, met een looptijd van 4 jaar. Instappen kan vanaf € 1.000. Ontvang de brochure en bekijk hoe deze investering werkt. Beleggen brengt risico's met zich mee. U kunt uw inleg verliezen. Lees het Basisprospectus op https://lnkd.in/eR5HJdqY voordat u een beleggingsbeslissing neemt.

How much of your sample's behaviour is your assay actually telling you? Fragmented assays leave data gaps and ambiguity. FIDA reports binding in the context of sample integrity: over 10 biophysical readouts from one sample, including binding affinity, kinetics, aggregation state, viscosity, polydispersity, quantification, stickiness/loss, labelling quality, structural correlation (PDB Correlator) and molecular size — all under identical assay conditions. Multiple questions, one assay. What is FIDA? Flow induced dispersion analysis is an in-solution biophysical technology based on first-principle physics. It resolves molecular size, binding and sample characteristics from one diffusion profile — replacing a stack of complementary assays with a single experiment, under native conditions. → Watch a webinar about FIDA Evolve: the newest FIDA instrument.

Why settle for a single yes/no readout on whether binding occurred? FIDA captures three functional analyses from one in-solution measurement: absolute molecular size (hydrodynamic radius), Lambda Dynamics (ratiometric fluorescence) and Binding-Related Intensity Change (BRIC). Three readouts means your confidence increases and your assay risk decreases, with no need to run separate, complementary assays. One assay, multiple answers. What is FIDA? Flow induced dispersion analysis is an in-solution biophysical technology based on first-principle physics. It resolves molecular size, binding and sample characteristics from one diffusion profile — replacing a stack of complementary assays with a single experiment, under native conditions. → Watch a webinar about Fida Evolve -> the new generation of FIDA.

Reimbursement status for approved drugs, competitors and standard of care, across the markets you work in. Run it on your own at no charge.

Using a standard biopsy, elive™ Test measures immune cell signals from a patient’s live tumor cells and gives you functional insight into how that tumor will respond to checkpoint therapy. Learn more and order: https://bit.ly/3U61FJr

Ervaring in mammografie? Zet jouw kennis en expertise in om toekomstige mammolaboranten op te leiden bij Bevolkingsonderzoek Nederland.

Selecting raw materials for biopharmaceutical manufacturing is more than matching a specification. Every manufactured batch has to be tested and documented to support the demanding requirements of regulated pharmaceutical manufacturing. So it is important to choose a supplier who understands both: regulatory expectations and manufacturing reality. To provide our customers with the best possible support, we developed PharmProve®. And PharmProve® is more than just a product portfolio, it offers: ✔️ Comprehensive batch documentation ✔️ Cleanroom suitable packaging formats ✔️ Endotoxin and bioburden testing ✔️ Regulatory confidence and reliable global supply chains ✔️ Multi-Compendial Raw Materials (e.g. EP, USP, JP, ChP) Who is PharmProve® designed for? Manufacturers of biopharmaceuticals, biosimilars, plasma-derived medicinal products and CDMO projects. 👉 Let’s talk about your current challenges. I look forward to helping you find the right solution!

Looking to strengthen your mobility portfolio? Discover how MyCondro™, a fermentation-derived chondroitin, can support the development of differentiated mobility solutions. Explore the infographic to learn more.

Do you know every grant available that is relevant for you? Do you know in which direction health tech capital is flowing? Do you know all the health tech discounts available? Do you know where to find the best models, playbooks & projections? Do you know every conference, investor days and founder meetups? ...Orbit does. For the past seven years, we have worked alongside founders, hospitals, investors and governments. Watching, up close, what actually makes health tech progress happen. Here's what we've learned: promising products don't stall because the science is wrong or the market isn't there. They stall on the boring stuff. Internal confusion, fragmented communication, missed follow-ups, unclear responsibilities, expenses gone rogue. Momentum fades. Opportunities vanish. The worst part? None of it has anything to do with the quality or scalability of your product. Orbit makes sure you stay on track.

¡Reserva la fecha! Una semana para aprender, conectar y seguir impulsando la medicina en Guatemala. Nos vemos en la 25 Semana Científica del 5 al 9 de octubre 🔬

Are you passionate about making a difference in public health? Don’t miss your chance to enrol in the Health Behaviour Change short course at the University of Oxford. - Gain insights into the foundations and drivers of health behaviours - Learn to design and evaluate effective health interventions - Study under the guidance of leading experts in the field This course will equip you with the skills needed to create and evaluate meaningful health improvements. ⏰ Application deadline: 8 October Learn more and apply: https://lnkd.in/e6W_ZjGM

Are you passionate about making a difference in public health? Don’t miss your chance to enrol in the Health Behaviour Change short course at the University of Oxford. ⏰ Application deadline: 8 October - Gain insights into the foundations and drivers of health behaviours - Learn to design and evaluate effective health interventions - Study under the guidance of leading experts in the field This course will equip you with the skills needed to create and evaluate meaningful health improvements. Learn more and apply: https://lnkd.in/e6W_ZjGM

How will your patient’s tumor respond to checkpoint inhibition? Using a standard core needle biopsy, elive™ Test measures whether a patient’s live tumor responds to checkpoint therapy using functional evidence, not static markers. Learn more and order: https://bit.ly/4hoF4kk

Looking for practical education on Alzheimer's disease and related dementias? This self-paced course provides actionable guidance on diagnosis, management, treatment considerations, and referral pathways to help support patients and caregivers throughout their journey.

Learn how and when to refer patients to Georgia Memory Net while building your knowledge of Alzheimer's Disease and Related Dementias (ADRD). This self-paced course also covers assessment, treatment strategies, and community resources available to patients and caregivers.

Not all chondroitin solutions are developed in the same way. Explore how fermentation-derived MyCondro™ can offer a distinctive approach for modern mobility formulations. Access the infographic for the key information.

I am honored to share that Fresenius Group has been named Investor’s Darling 2026 by manager magazin, Berenberg, and HHL Leipzig Graduate School of Management securing the highest overall score in this year’s ranking and taking first place in the DAX40 category. This is a very meaningful recognition for Fresenius. When we started our #FutureFresenius journey in 2022, one of our most important priorities was to rebuild trust with the capital markets and restore confidence in our company. Improving our capital market communication was therefore a fundamental objective. We knew it would enable us to provide stakeholders with a clear understanding of our position, our priorities, and our ambitions. This award is therefore a much-appreciated external validation of the significant progress we have made throughout, and especially during, the Rejuvenate phase of our strategy. It reflects how far we have come as an organization and how strongly we have established capital market communication with all our stakeholders. I would like to sincerely thank our Fresenius Investor Relations team under the leadership of Nick S. This recognition belongs to all of you. Going from second place last year to Investor's Darling this year is a remarkable achievement. More importantly, it is a well-deserved recognition of the outstanding work you do every day. Let's also look at this award as a challenge to keep raising the bar as we enter the next phase of our #FutureFresenius journey, Reimagine. Congratulations to our Investor Relations team and to the many colleagues across Fresenius whose contributions helped make this achievement possible. HHL Leipzig Graduate School of Management Prof. Dr. Henning Zülch

💡Register for our October webinar: 'From Scoping to Systematic: Choosing the Right Literature Review for Your Evidence Needs.' Join us in collaboration with The Evidence Base for our upcoming discussion on how to navigate the literature review spectrum and select the most appropriate approach for different evidence needs and decision contexts across the pharmaceutical product lifecycle. 🗓️ Tuesday, October 6, 2026 🕒 10:00 AM ET | 7:00 AM PT | 3:00 PM BST | 4:00 PM CEST Our speakers Zarmina K., Samara Ferguson, and Priti Jhingran will discuss how scoping, targeted, and systematic reviews differ in purpose, rigor, and resource requirements, and how each approach can support evidence generation and informed decision-making. The discussion will also explore how literature reviews fit within integrated evidence generation planning (IEGP) and can help inform evidence decisions throughout the product lifecycle. Places are limited. Reserve yours at: https://lnkd.in/ehAhcKx6 #EvidenceSynthesis #HEOR #MarketAccess #RWE #HTA #IEGP

Iowa's Cardiovascular Health Hub letter of intent is due October 19, and applications close November 17. A single rural Iowa organization can apply on its own, and care coordination and chronic disease management are allowable uses. Droxi takes clinical inbox work off your providers inside athenahealth and eClinicalWorks: 5.1+ hours back per provider, every week. If you're putting an application together, we can help you scope the technology piece and send you a quote for it.

Bring a new dimension to your digital restorative workflow. Explore CEREC Cercon 4D™ Multidimensional Zirconia from Dentsply Sirona.

An AVI machine can have hundreds, if not thousands, of parameters. The key is to identify which ones are critical to the quality outcome of your process.

Medical Affairs is evolving. So should HCP engagement. EPIKAST combines scientific expertise, and intelligent execution to enable scalable, PEER-LEVEL HCP engagement. Explore what a different model could deliver.

A different approach to HCP engagement starts with a different operating model. EPIKAST combines scientific expertise, and intelligent execution to support meaningful Medical Affairs engagement at scale. Explore the model.